M1FG
FATE icon

Mach-1 Financial Group’s Fate Therapeutics FATE Stock Holding History

Mach-1 Financial Group’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-100,869
Closed -$480K – 214
2023
Q2 		$480K Buy
+100,869
New +$557K 0.14% 154
2023
Q1 		– Sell
-51,574
Closed -$520K – 289
2022
Q4 		$520K Buy
+51,574
New +$969K 0.17% 137

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Mach-1 Financial Group's FATE Position: Q3 2023 in Review

Mach-1 Financial Group sold out of Fate Therapeutics (FATE) in Q3 2023, closing a stake of 100,869 shares — an estimated $480K sold.

Mach-1 Financial Group first reported a position in FATE in Q4 2022 and held it in 2 quarters. The position peaked at $520K in Q4 2022. 170 funds tracked by Wall St. Rank hold FATE as of Q3 2023.

  • Mach-1 Financial Group reported no remaining Fate Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Mach-1 Financial Group sold 100,869 Fate Therapeutics shares in Q3 2023, an estimated $480K.
  • Mach-1 Financial Group first reported a position in Fate Therapeutics in Q4 2022 and held it in 2 quarters.
  • Mach-1 Financial Group's Fate Therapeutics position peaked at $520K in Q4 2022.
  • 170 funds tracked by Wall St. Rank held Fate Therapeutics as of Q3 2023.

Based on Mach-1 Financial Group's 13F filing for Q3 2023, filed 17 Oct 2023.